Efficacy of amoxycillin/clavulanic acid in experimental Staphylococcus aureus endocarditis in the rat.
The efficacy of amoxycillin/clavulanic acid was compared with that of flucloxacillin, vancomycin and amoxycillin in an experimental model of Staphylococcus aureus endocarditis. Doses of the antibiotics were selected to produce peak concentrations in rat serum similar to those achievable in man after administration of parenteral therapeutic doses. Amoxycillin clavulanic acid was more effective than amoxycillin alone against endocarditis caused by beta-lactamase producing strains of Staph. aureus, illustrating the beta-lactamase inhibitory activity of clavulanic acid in vivo. Amoxycillin/clavulanic acid was as effective as flucloxacillin in these infections whereas vancomycin was generally less active. These results illustrate the clinical potential of amoxycillin/clavulanic acid in the prophylaxis, or in the therapy of severe staphylococcal infections.
Catherall
E J
EJ
SmithKline Beecham Pharmaceuticals, Betchworth, Surrey, UK.
Irwin
R
R
Mizen
L W
LW
D000658:Amoxicillin / Q000097:blood / Q000627:therapeutic use*; D019980:Amoxicillin-Potassium Clavulanate Combination; D000818:Animals; D002969:Clavulanic Acids / Q000097:blood / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000097:blood / Q000627:therapeutic use; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D005436:Floxacillin / Q000097:blood / Q000627:therapeutic use; D008297:Male; D051381:Rats; D013045:Species Specificity; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects; D013997:Time Factors; D014640:Vancomycin / Q000097:blood / Q000627:therapeutic use
D002969:Clavulanic Acids; D005436:Floxacillin; D014640:Vancomycin; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin